Abstract
For diabetes treatment, the newest kid on the block is canagliflozin (Invokana), which lowers blood glucose levels by decreasing renal tubular reabsorption of glucose and increasing urinary glucose excretion. In this double-blind, industry-sponsored trial, researchers randomized 756 patients with longstanding type 2 diabetes — all of whom …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
